In a 2 year longitudinal fingolimod study, we investigated the evolution of white matter integrity in the brain of relapsing-remitting multiple sclerosis (RRMS) patients under fingolimod treatment. Based on dMRI metrics from HARDI scans and statistical analysis, we found that MS patients experience a continued decline in white matter integrity during the first year of treatment with fingolimod with stabilization during the second year. Without a control group, it is unclear if these trends reflect on the impact of a treatment on disease progression.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords